- Open Access
AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia
- Han-Tan Chai†1,
- Hon-Kan Yip†1, 2, 3, 4, 5,
- Cheuk-Kwan Sun6,
- Shu-Yuan Hsu2, 7 and
- Steve Leu2Email author
© The Author(s). 2016
- Received: 18 January 2016
- Accepted: 31 May 2016
- Published: 4 June 2016
Erythropoietin (EPO) has been demonstrated to enhance recovery in ischemic organs through enhancing angiogenesis. In this study, we used an experimental critical limb ischemia (CLI) rat model to reveal the underlying mechanisms and directly examine the benefits of the anti-apoptotic capacity of EPO in the acute phase of limb ischemia and following blood flow recovery.
To determine the role of the JAK2/STAT pathway in EPO-enhanced recovery after CLI, male Sprague-Dawley rats (n = 8 for each group) were divided into group 1 (normal control), group 2 (CLI treated with normal saline), group 3 (CLI treated with EPO), group 4 (CLI treated with AG490, a JAK2 inhibitor), and group 5 (CLI treated with EPO and AG490). Animals were sacrificed either at day 1 or day 14 and biochemical and histopathological examination of ischemic quadriceps were conducted.
At day 1, EPO administration reduced expression levels of apoptotic indices and activated the JAK2/STAT pathway; this activation was inhibited by additional AG490 treatment. Furthermore, the decrease in the size of the infarcted area, as well as activation of ERK1/2 and JNK showed similar regulatory trends with EPO or AG490 treatment. Of Interest, EPO and AG490 in combination showed a synergistic effect, increasing expression levels of antioxidants (GR, GPx, NQO-1) and decreasing transcriptional levels of pro-inflammatory factors (TNF-α, NF-kB). At day 14, laser Doppler analysis showed that the blood flow recovery was enhanced by EPO, AG490, or combined treatment.
Although inhibition of the JAK2/STAT pathways reduces the anti-apoptotic effects of EPO in the early phase of CLI, the benefits of AG490 in anti-inflammation and anti-oxidation still play a positive role in enhancing blood flow recovery after CLI.
- Critical limb ischemia
Peripheral arterial disease (PAD) is caused by chronic inflammatory processes associated with atherosclerosis . Critical limb ischemia (CLI), which results in significant blood flow reduction in feet and hands, is the most severe form of PAD . Although endovascular intervention and open surgical techniques are widely used treatments for CLI, amputation remains the final option for a certain subset of patients [3–5]. Under general medical care conditions, one year after diagnosis of CLI, half of patients are dead or alive with amputations, while only quarter of patients see symptoms resolve . So far, there is no satisfying pharmacologic therapy to efficiently reverse arterial occlusive lesions, or the subsequent impaired perfusion in ischemic limbs of patients . The purpose of pharmacologic treatment for CLI includes risk factor modification and efforts to improve blood flow [7, 8]. However, only patients with mild to moderate intermittent claudication are advised to undergo pharmacologic therapy . Therefore, alternate treatment approaches are urgently needed for CLI.
Erythropoietin (EPO), a 165 kDa secreted glycoprotein, was first characterized as a hematopoietic factor and has been widely used for the clinical treatment of anemia [9–11]. EPO not only promotes the proliferation and differentiation of erythroid precursors, but also plays an important role as an anti-apoptotic factor for hematopoietic cells . In general, the expression level of erythropoietin is upregulated under hypoxic conditions and mediated by a transcription factor, hypoxia inducible factor-1 (HIF-1) [13, 14]. EPO is mainly produced by cells of the peritubular capillary endothelium of the kidney , while EPO receptors (EPOR) are widely expressed in various tissues, including brain, retina, heart, kidney, smooth muscle, myocardium, and endothelium . The EPO-mediated protective responses in anti-apoptosis are also found in non-hematopoietic cells, e.g., renal tubular cells , neurons , retina cells , cardiomyocytes , and endothelial cells . Recent studies also demonstrated that EPO plays multiple functional roles in anti-inflammation [15, 20], angiogenesis [21, 22], and in endothelial response to increasing nitric oxide production . The therapeutic efficacy of EPO in amelioration of organ ischemic injury or ischemia-reperfusion injury has been evaluated through experimental animal models as well as clinical applications [24–28].
EPO is activated through its binding to the EPO receptor (EPOR), which is composed of two identical subunits [29, 30]. After binding, the receptor is dimerized and Janus kinase-2 (JAK2) is then recruited to the receptor complex [29, 30]. After binding of EPO and EPOR, several substrates of JAK2, including transcription factor signal transducer and activator of transcription (STAT) are recruited to the docking site of EPOR [29, 30]. STATs are phosphorylated by JAK kinases, leading to dimerization and subsequent translocation to the nucleus [29, 30]. After nuclear translocation, STATs bind to promoters of several genes involved in anti-apoptosis, including Bcl-xL, Bcl-2 and c-Myc. However, although the activation of JAK2/STATs plays an anti-apoptotic role in organ injury, this activated signaling is also involved in upregulation of pro-inflammatory cytokine generation [31–33]. Inhibition of JAK2 activity through its inhibitors (i.e., AG490) has been applied as an approach to treat ischemia-reperfusion injury and autoimmune arthritis in animal models [34, 35]. Hence, revealing the underlying mechanism of EPO-mediated cellular response is important for the selection and adjustment of clinical application of EPO in different types of organ injuries.
Although EPO has been demonstrated to have therapeutic efficacy in treating critical limb ischemia in experimental animal models , the underlying mechanisms are still not completely clear. In the present study, we applied rat CLI models with a JAK2 inhibitor to determine the whether the JAK2/STAT pathway is essential for EPO-mediated blood flow recovery after CLI. In addition, whether the anti-inflammatory role of AG490 contributes in injury recovery from CLI was also examined.
Animal model of critical limb ischemia
Pathogen-free, adult male Sprague-Dawley (SD) rats (n = 60) weighing 320-350 g (Charles River Technology, BioLASCO Taiwan Co. Ltd., Taiwan) were used in this study (n = 16 for each group): Group 1, normal control; Group 2, critical limb ischemia (CLI) with normal saline; Group 3, CLI with EPO; Group 4, CLI with AG490; Group 5, CLI with EPO and AG490. EPO was injected intramuscularly (1000 IU/kg), while AG490 was injected intraperitoneally (3 mg/kg). EPO and AG490 were administrated at 30 min, 24 h, and 48 h after induction of CLI. Animals were sacrificed at either day 1 or day 14 (8 animals from each group were sacrificed at each time-point). For induction of critical limb ischemia by ligation of the femoral artery, rats were placed in a supine position on a warming pad at 37 °C with the left hind limbs shaved. Under sterile conditions, the left femoral artery, small arterioles and circumferential femoral artery were exposed and ligated over their proximal and distal portions before removal. To avoid the presence of collateral circulation, the branches were removed together. After sacrifice, the left quadricep muscles were collected for individual study.
Measurement of blood flow with laser doppler
Rats were anesthetized by inhalation of 2.0 % isoflurane prior to CLI induction and on days 2 and 14 after CLI induction prior to being sacrificed (n = 8 for each group). The rats were placed in a supine position on a warming pad at 37 °C. After being shaved over bilateral hind limbs and inguinal areas, blood flow was surveyed by a Laser Doppler scanner (moorLDLS, Moor, UK). The ratio of blood flow in the left hind limb (ischemic) to that in the right side (normal) was applied to determine the blood flow recovery after CLI.
Quantitative reverse transcription-polymerase chain reaction
Quantitative mRNA levels were determined using real-time reverse transcription-polymerase chain reaction (RT-PCR) with the Applied Biosystems 7900 HT Sequence Detection System (Applied Biosystems) and TaqMan Gene Expression Assay as previously described .
Western blot analysis
Equal amounts (10-30 μg) of protein extracts from ischemic quadriceps of the animals (n = 6 for each group) were loaded and separated by SDS-PAGE using 7 or 12 % acrylamide gradients. Proteins were then transferred to nitrocellulose membranes. The membranes were incubated with monoclonal antibodies against JAK2 (1:1000, Abcam), phosphorylated JAK2 (1:1000, Abcam), STAT1 (1: 1000, Cell Signaling), phosphorylated STAT1 (1: 1000, Cell Signaling), STAT3 (1:500, Cell Signaling), phosphorylated STAT3 (1:1000, Cell Signaling), STAT5 (1:1000, Abcam), phosphorylated STAT5 (1:500, Abcam), Akt (1:1000, Cell Signaling), phosphorylated Akt (1:2000, Cell Signaling), JNK (1:500, Sigma), phosphorylated JNK (1:1000, Abcam), ERK1/2 (1:1000, Cell Signaling), and phosphorylated ERK1/2 (1:2000). Signals were detected with HRP-conjugated goat anti-mouse or goat anti-rabbit IgG. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences) which was then exposed to Biomax L film (Kodak). For quantification, ECL signals were digitized using Labwork software (UVP).
Histopathological and immunostaining
The immunofluorescence (IF) staining and immunohistochemical (IHC) staining were performed as previously described . In brief, fixed cryosections (10 μm) of quadriceps were incubated with antibodies against CD31 (1:200, Abcam), EPOR (1:500, Abcam), or α-SMA (1:400, Millipore) at 4 °C overnight, followed by incubation with fluorescence or HRP-conjugated secondary antibodies. For quantification, ten randomly selected HPFs (high power fields, 200×) were analyzed in each section. The mean number per HPF for each animal was then determined by summation of all numbers divided by 30.
Data was expressed as mean values (mean ± SD). The significance of differences between two groups was evaluated with t-test. The significance of differences among groups was evaluated using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Statistical analysis was performed using Prism 5 statistical software (GraphPad Software, La Jolla, CA, USA). A probability value of less than 0.05 was considered statistically significant.
AG490 administration inhibits phosphorylation of STATs in quadriceps
EPO administration showed an anti-apoptotic activity in ischemic quadriceps
Quantitated real-time reverse transcription polymerase chain reaction (RT-qPCR) was also performed to confirm the results of TUNEL assay (Fig. 2g-i). RT-qPCR examination of transcripts of Bax (Fig. 2h) and caspase-3 (Fig. 2i), two pro-apoptotic indices showed similar regulatory trends to those observed in the TUNEL assay. In contrast, mRNA expression levels of Bcl-2, an anti-apoptotic factor, were decreased after CLI induction and reverted with EPO treatment (Fig. 2g). In addition, the blocking of EPO-mediated cellular protective function against apoptosis in ischemic quadriceps by AG490 was confirmed by RT-qPCR (Fig. 2g-i).
Infarct area in ischemic quadriceps is reduced by EPO treatment
EPO and AG490 contribute to anti-inflammation and anti-oxidation in the ischemic quadriceps
The mRNA expression levels of anti-oxidant genes, heme oxygenase (HO)-1, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione reductase (GR), and glutathione peroxidase (GPx) were increased after CLI induction (Fig. 4d-g). Treatment with EPO, AG490, or combined EPO and AG490 all further increased the transcripts. Showing the same trend as IL-10, EPO and AG490 synergistically enhanced the expression levels of anti-oxidants (Fig. 4d-g).
Phosphorylation of ERK1/2 with that activation of the JAK2/STAT pathway
Activation of JAK2 signaling is important in EPO-mediated increased expression of EPO receptors
Enhanced blood flow recovery with EPO and AG490 treatment
In the present study, we directly applied an experimental rat model with critical limb ischemia to evaluate the effects of EPO and JAK2 inhibitor AG490 in preventing apoptosis as well as in enhancing blood recovery in ischemic limbs. In addition, we also performed biochemical analysis, histopathological examination, and immunostaining to detect the activation of underlying signaling responding to CLI insults and EPO treatment. The results suggest that EPO can prevent cellular apoptosis and reduce the size of the infarct area in the ischemic quadriceps during the acute phase of CLI (Figs. 2 and 3). We also found that the phosphorylation of STAT1 and STAT5, but not STAT3, was activated by EPO-mediated JAK2 activation in the CLI areas (Fig. 1). Moreover, our results showed that the JAK2 inhibitor AG490 blocked the activation of JAK2/STAT signaling and abolished the anti-apoptotic efficacy of EPO (Figs. 1-3). However, AG490-only treatment increased the synthesis of anti-oxidants and also reduced the gene expressions of inflammatory factors (Fig. 4). It is worth noting that the combined EPO and AG490 treatment showed synergistic effects in enhancing anti-oxidation and anti-inflammation. At day 14 after CLI, we found that EPO, AG490 and combined EPO and AG490 therapies all increased the blood flow recovery after CLI (Figs. 7 and 8). In addition, results from Western blots showed that the activation of JNK and ERK pathways in quadriceps were regulated by ischemic stress, EPO, and AG490 (Fig. 5).
EPO-mediated intracellular signaling in ischemic limbs
Among STAT transcription factors, STAT5 is the most prominent substrate to be phosphorylated with JAK2 [39, 40], while phosphorylated STAT3 and STAT1 are only found in certain kinds of cells [41, 42]. In the present study, we noted that the phosphorylation of STAT5 and STAT1, but not STAT3, were upregulated by EPO and along with the phosphorylation levels of JAK2. In addition to the JAK2/STAT pathways, several mitogen-activated protein kinases (MAPKs) signaling cascades, including ERK, p38, and JNK, have been reported to play roles in delivering ERO/EPOR signals [43–45]. Results in this study also demonstrated that the expression levels and phosphorylation levels of ERK1/2 were upregulated by EPO and reverted with additional AG490 treatment (Fig. 5). Although previous studies considered the activation of PI3K is important for EPO-mediated phosphorylation of ERK , the activation of Akt, another PI3K kinase substrate, did not increase after EPO treatment in ischemic quadriceps (Fig. 5). Hence, instead of PI3K, other kinase facility, i.e. Ras/Raf, may contribute in the EPO-mediated, JAK2-dependent, activation of MAPKs after CLI. Although tyrosine phosphorylation of STATs with JAK kinase is found in most cells, some reports demonstrated the existence of JAK2-independent phosphorylation of STAT5 [47, 48]. To clarify this issue, we combined EPO and AG490 to treat rat CLI and found that STAT5 activation in ischemic quadriceps was in a JAK2-dependent manner. The inhibitory effect of AG490 in JAK2/STAT signaling has been found in tissues with different pathological stresses, including myocardial hypertrophy , liver ischemia-reperfusion , traumatic brain injury , and chronic renal disease . In the present study, we further confirmed the effect of AG490 in inhibiting the activation and JAK2 and its downstream phosphorylation of STAT1, STAT3, and STAT5 in the critical limb ischemia model.
Upregulation of anti-inflammatory and anti-oxidative genes by EPO and AG490
In addition to roles in erythropoiesis, other functions of EPO, including anti-apoptosis and angiogenesis, have also been demonstrated [22, 30]. In this study, through the CLI rat model, we found that EPO regulated the gene expression levels of inflammatory and anti-oxidative proteins and showed a protective effect against inflammation and oxidation. Of note, AG490 also provided similar anti-inflammatory and anti-oxidation effects, despite its roles in blockage of JAK2 activity and impairing anti-apoptosis. The distinct role of AG490 may be through inhibition of JAK2, which reduces gene expression of anti-apoptotic factors in endothelial and skeletal muscle cells, and also inhibits inflammatory cytokine release, proliferation, and activation in inflammatory cells. Hence, the distinct physiological roles of AG490 on different kinds of cells may provide contradictory effects in enhancing recovery from ischemic injury.
Combined EPO and AG490 to treat CLI
Although the anti-inflammatory capacity of AG490 reduced the generation of inflammatory factors and also increased the expression levels of anti-oxidants, its role in blocking JAK2 activity impaired the anti-apoptotic effects of EPO in the acute phase of CLI. These seemingly contradictory roles may explain the controversy surrounding the effects of AG490 in the treatment of ischemia-reperfusion injury in different organs [35, 52–54]. In this study, the examination of blood flow examination using laser Doppler analysis also showed both EPO and AG490 treatments enhance the blood flow recovery after CLI; however, no additional benefit was found in the combined treatment group. Since JAK2 activity is critical in the function of EPO in preventing ischemia-induced cellular apoptosis, the application of AG490 should be avoided in the acute phase of CLI. Combined EPO and delayed AG490 adminstration may provide better therapeutic efficacy in treating CLI.
This study indicates that JAK2-dependent STAT activation plays an important role in EPO-mediated enhanced blood flow recovery after CLI induction in rats. Although AG490 inhibits the EPO-induced JAK2/STAT activation in the acute phase of CLI, the benefits of AG490 in anti-inflammation and anti-oxidation still provide a better outcome in rats with CLI. The functional effects of EPO in anti-apoptosis, anti-inflammation, and anti-oxidation provide therapeutic efficacy for injury recovery after critical limb ischemia.
The authors thank supports from Chang Gung Medical Research Program Grant (Grant number: CMRPG 8B1221 to HTC; CMRPG 8C1011 and CMRPG 8C1012 to SL) and Ministry of Science and Technology, Taiwan (Grant number MOST-102-2320-B-182A-001-MY3 to SL).
HTC and SL participated in the design of the study, data acquisition and analysis as well as drafting the manuscript. HTC, CKS, and SYH were responsible for data acquisition, analysis, and interpretation. SL and HKY conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All animal experimental procedures were approved by the Institute of Animal Care and Use Committee of Kaohsiung Chang Gung Memorial Hospital (Approval No. 2012032601) and performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, National Academy Press, Washington, DC, USA, revised 1996).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Shamoun FE, Fankhauser GT, Mookadam M. Vascular medicine: aortic and peripheral arterial disease. Prim Care. 2013;40(1):169–77.View ArticlePubMedGoogle Scholar
- Slovut DP, Sullivan TM. Critical limb ischemia: medical and surgical management. Vasc Med. 2008;13(3):281–91.View ArticlePubMedGoogle Scholar
- Chung J, Timaran DA, Modrall JG, Ahn C, Timaran CH, Kirkwood ML, Baig MS, Valentine RJ. Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia. J Vasc Surg. 2013;58(4):972–80.View ArticlePubMedGoogle Scholar
- Ortmann J, Gahl B, Diehm N, Dick F, Traupe T, Baumgartner I. Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency. J Vasc Surg. 2012;56(3):737–745 e731.View ArticlePubMedGoogle Scholar
- Simons JP, Schanzer A, Nolan BW, Stone DH, Kalish JA, Cronenwett JL, Goodney PP, Vascular Study Group of New E. Outcomes and practice patterns in patients undergoing lower extremity bypass. J Vasc Surg. 2012;55(6):1629–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Gasper WJ, Runge SJ, Owens CD. Management of infrapopliteal peripheral arterial occlusive disease. Curr Treat Options Cardiovasc Med. 2012;14(2):136–48.View ArticlePubMedGoogle Scholar
- Moise MA, Kashyap VS. Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy. Curr Treat Options Cardiovasc Med. 2011;13(2):114–28.View ArticlePubMedGoogle Scholar
- Dawson DL, Mills JL. Critical limb ischemia. Curr Treat Options Cardiovasc Med. 2007;9(2):159–70.View ArticlePubMedGoogle Scholar
- Ramanath V, Gupta D, Jain J, Chaudhary K, Nistala R. Anemia and chronic kidney disease: making sense of the recent trials. Rev Recent Clin Trials. 2012;7(3):187–96.View ArticlePubMedGoogle Scholar
- Debeljak N, Sytkowski AJ. Erythropoietin and erythropoiesis stimulating agents. Drug Test Anal. 2012;4(11):805–12.View ArticlePubMedGoogle Scholar
- Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat. 2012;19(2):77–87.View ArticlePubMedGoogle Scholar
- Sui X, Krantz SB, Zhao ZJ. Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol. 2000;110(1):63–70.View ArticlePubMedGoogle Scholar
- Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F. The role and regulation of hypoxia-inducible factor-1alpha expression in brain development and neonatal hypoxic-ischemic brain injury. Brain Res Rev. 2009;62(1):99–108.View ArticlePubMedGoogle Scholar
- Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Erbayraktar S, Yilmaz O, Gokmen N, Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep. 2003;2(6):465–70.PubMedGoogle Scholar
- Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother. 2010;64(10):681–5.View ArticlePubMedGoogle Scholar
- Adelibieke Y, Shimizu H, Saito S, Mironova R, Niwa T. Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of Akt phosphorylation. Circ J. 2013;77(5):1326–36.View ArticlePubMedGoogle Scholar
- Zhong YS, Yao HP, Deng LF, Cheng Y, Min YJ. Effect of erythropoietin on the survival of retinal neurocytes in culture upon serum withdrawal. Neurosciences. 2010;15(3):152–8.PubMedGoogle Scholar
- Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308(4):990–4.View ArticlePubMedGoogle Scholar
- Zhang X, Li QY, Xiao BG. Anti-inflammatory effect of erythropoietin therapy on experimental autoimmune encephalomyelitis. Int J Neurosci. 2012;122(5):255–62.View ArticlePubMedGoogle Scholar
- Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev. 2010;19(1):1–4.View ArticlePubMedGoogle Scholar
- Hou X, Wu X, Ma J, Lv X, Jin X. Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia. Mol Biol Rep. 2010;37(3):1467–75.View ArticlePubMedGoogle Scholar
- Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 2014;15(6):10296–333.View ArticlePubMedPubMed CentralGoogle Scholar
- Gut N, Piecha G, Aldebssi F, Schaefer S, Bekeredjian R, Schirmacher P, Ritz E, Gross-Weissmann ML. Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function. Am J Nephrol. 2013;38(2):124–35.View ArticlePubMedGoogle Scholar
- Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int. 2006;19(11):919–26.View ArticlePubMedGoogle Scholar
- Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44(4):473–9.View ArticlePubMedGoogle Scholar
- Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S, Yuen CM, Tan TY, Lan MY, Liou CW, et al. Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care. 2011;15(1):R40.View ArticlePubMedPubMed CentralGoogle Scholar
- Chua S, Leu S, Lin YC, Sheu JJ, Sun CK, Chung SY, Chai HT, Lee FY, Kao YH, Wu CJ, et al. Early erythropoietin therapy attenuates remodeling and preserves function of left ventricle in porcine myocardial infarction. J Invest Med. 2011;59(3):574–86.View ArticleGoogle Scholar
- Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14 Suppl 2:22–8.View ArticlePubMedGoogle Scholar
- Bittorf T, Jaster R, Ludtke B, Kamper B, Brock J. Requirement for JAK2 in erythropoietin-induced signalling pathways. Cell Signal. 1997;9(1):85–9.View ArticlePubMedGoogle Scholar
- Huang C, Ma R, Sun S, Wei G, Fang Y, Liu R, Li G. JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J Neuroimmunol. 2008;204(1-2):118–25.View ArticlePubMedGoogle Scholar
- Kandalam U, Clark MA. Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul Pept. 2010;159(1-3):110–6.View ArticlePubMedGoogle Scholar
- Yang X, He G, Hao Y, Chen C, Li M, Wang Y, Zhang G, Yu Z. The role of the JAK2-STAT3 pathway in pro-inflammatory responses of EMF-stimulated N9 microglial cells. J Neuroinflammation. 2010;7:54.View ArticlePubMedPubMed CentralGoogle Scholar
- Park JS, Lee J, Lim MA, Kim EK, Kim SM, Ryu JG, Lee JH, Kwok SK, Park KS, Kim HY, et al. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol. 2014;192(9):4417–24.View ArticlePubMedGoogle Scholar
- Freitas MC, Uchida Y, Zhao D, Ke B, Busuttil RW, Kupiec-Weglinski JW. Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl. 2010;16(5):600–10.PubMedPubMed CentralGoogle Scholar
- Leu S, Lu HI, Sun CK, Sheu JJ, Chen YL, Tsai TH, Yeh KH, Chai HT, Chua S, Tsai CY, et al. Retention of endothelial progenitor cells in bone marrow in a murine model of endogenous tissue plasminogen activator (tPA) deficiency in response to critical limb ischemia. Int J Cardiol. 2014;170(3):394–405.View ArticlePubMedGoogle Scholar
- Sun CK, Leu S, Sheu JJ, Tsai TH, Sung HC, Chen YL, Chung SY, Ko SF, Chang HW, Yip HK. Paradoxical impairment of angiogenesis, endothelial function and circulating number of endothelial progenitor cells in DPP4-deficient rat after critical limb ischemia. Stem Cell Res Ther. 2013;4(2):31.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol. 2007;292(5):H2467–74.View ArticlePubMedGoogle Scholar
- Bittorf T, Seiler J, Ludtke B, Buchse T, Jaster R, Brock J. Activation of STAT5 during EPO-directed suppression of apoptosis. Cell Signal. 2000;12(1):23–30.View ArticlePubMedGoogle Scholar
- Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem. 1996;271(50):32430–7.View ArticlePubMedGoogle Scholar
- Yamamura Y, Senda H, Noda M, Ikawa Y. Activation of the JAK1-STAT5 pathway by binding of the Friend virus gp55 glycoprotein to the erythropoietin receptor. Leukemia. 1997;11 Suppl 3:432–4.PubMedGoogle Scholar
- Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1275–83.View ArticlePubMedGoogle Scholar
- Lee SM, Nguyen TH, Park MH, Kim KS, Cho KJ, Moon DC, Kim HY, Yoon DY, Hong JT. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun. 2004;320(4):1087–95.View ArticlePubMedGoogle Scholar
- Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res. 2003;71(5):659–69.View ArticlePubMedGoogle Scholar
- Shan R, Price JO, Gaarde WA, Monia BP, Krantz SB, Zhao ZJ. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. Blood. 1999;94(12):4067–76.PubMedGoogle Scholar
- Schmidt EK, Fichelson S, Feller SM. PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors. BMC Biol. 2004;2:7.View ArticlePubMedPubMed CentralGoogle Scholar
- Mannello F, Tonti GA. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Oncologist. 2008;13(7):761–8.View ArticlePubMedGoogle Scholar
- Tsuji-Takayama K, Otani T, Inoue T, Nakamura S, Motoda R, Kibata M, Orita K. Erythropoietin induces sustained phosphorylation of STAT5 in primitive but not definitive erythrocytes generated from mouse embryonic stem cells. Exp Hematol. 2006;34(10):1323–32.View ArticlePubMedGoogle Scholar
- Manukyan I, Galatioto J, Mascareno E, Bhaduri S, Siddiqui MA. Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective alphaB-crystallin gene expression in response to hypertrophic stimuli. J Cell Mol Med. 2010;14(6B):1707–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao JB, Zhang Y, Li GZ, Su XF, Hang CH. Activation of JAK2/STAT pathway in cerebral cortex after experimental traumatic brain injury of rats. Neurosci Lett. 2011;498(2):147–52.View ArticlePubMedGoogle Scholar
- Li R, Yang N, Zhang L, Huang Y, Zhang R, Wang F, Luo M, Liang Y, Yu X. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol. 2007;27(6):580–9.View ArticlePubMedGoogle Scholar
- Clarke C, Sakai N, Tevar AD, Schuster R, Edwards MJ, Lentsch AB. STAT3 does not regulate acute liver injury after ischemia/reperfusion. J Surg Res. 2011;171(2):814–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheppudira BP, Girard BM, Malley SE, Dattilio A, Schutz KC, May V, Vizzard MA. Involvement of JAK-STAT signaling/function after cyclophosphamide-induced bladder inflammation in female rats. Am J Physiol Renal Physiol. 2009;297(4):F1038–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Chattong S, Tanamai J, Kiatsomchai P, Nakatsu M, Sereemaspun A, Pimpha N, Praditpornsilpa K, Rojanathanes R, Sethpakadee A, Tungsanga K, et al. Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production. Br J Pharmacol. 2013;168(1):189–99.View ArticlePubMedPubMed CentralGoogle Scholar